Table 1.
Basic characteristics of included literatures, characteristics of study subjects, and quality evaluation scores.
| References | Patient characteristics | Patient age (years) | BMI (kg/m2) | Number of cases (E/C) | Experimental group intervention | Control group intervention | Intervention time (Median) | Outcome indicators |
|---|---|---|---|---|---|---|---|---|
| Song et al. (9) | Obese female | 34.92 ± 6.46 | 29.99 ± 4.27 | 13/15 | Schisandra chinensis fruit | Placebo | 3 mo | (a–c) |
| Li et al. (10) | Obese patients with ovarian syndrome | 20–40 | 27–29.9 | 50/50 | Chinese herbs for kidney resolving phlegm+ acupuncture |
Oral ethinylestradiol cyproterone tablets | 3 mo | (a–g) |
| Chen et al. (11) | Patients with metabolic syndrome | 30.5 ± 6.2 | 32.0 ± 6.58 | 30/30 | Wendan Decoction | Placebo | 1 mo | (a–g) |
| Zhang et al. (12) | Obesity 2 Patients with type 2 diabetes | 41–68 | 19–33 | 52/54 | Shenqi Compound Decoction | Placebo | 2 mo | (a–c) |
| Li et al. (13) | Obese type 2 diabetic patients | 51.09 ± 11.34 | N/A | 49/49 | Wenyang Yiqi Huoxue Recipe+Metformin | Metformin | 2 mo | (a–g) |
| Liu et al. (14) | Obese Patients | 18–65 | >28 | 24/24 | Qi Wei Bai Zhu San | Placebo | 3 mo | (b,c) |
| Du et al. (15) | Patients with glucose resistance | 28–70 | N/A | 20/20 | Jiangzhuo Mixture | Placebo | 1 mo | (a–c) |
| Chen et al. (16) | Patients with type 2 diabetes | 59.81 ± 5.44 | N/A | 40/40 | Fuzi Lizhong Pills+Glichi | Gleetzil | 1 mo | (a–g) |
| Zhang et al. (17) | Patients with metabolic syndrome | 60.3 ± 6.7 | 28.64 ± 1.69 | 91/89 | Lidan Huatan Huoxue Recipe | Placebo | 6 mo | (b,c) |
| Liu et al. (18) | Spleen deficiency syndrome patients with type 2 diabetes | 54.37 ± 6.45 | 25.01 ± 3.98 | 48/47 | Yiqi Bupi Recipe | Placebo | 2 mo | (a–g) |
N/A, Not available; E/C, Experimental/Control group.
Outcomes: (a) TC; (b) TG; (c) HDL; (d) number of Enterobacteriaceae; (e) number of Enterococcus; (f) number of Lactobacillus; (g) number of Bifidobacterium.